Summary
We have studied the pharmacokinetics of methylphenidate enantiomers after the oral administration of different doses of racemic methylphenidate to one patient with narcolepsy and to four healthy volunteers.
The plasma concentrations of (+)-methylphenidate were much higher than those of (−)-methylphenidate after each dose in all subjects. In the patient the oral clearance (CL/f) of (+)-methylphenidate fell 3-fold and the area under the concentration-time curve (AUC) rose 7-fold when the dose was increased from 20 to 40 mg (from 0.27 to 0.53 mg·kg−1), in spite of the relatively constant terminal half-life of 2.6–2.7 h.
Similar dose-dependency was also observed in the healthy volunteers in the dose range of 10–60 mg (0.12–0.77 mg·kg−1). The mean value of CL/f for the 40 mg dose was significantly lower than that for the 20 mg dose. The mean AUC of the (+)-isomer corrected to a dose of 10 mg increased significantly between the 20 mg and 40 mg doses.
In the urine (+)- and (−)-ritalinic acid were excreted for 48 h after each dose as 32–37% and 34–40% of the dose respectively. The mean total recoveries (sum of enantiomers of methylphenidate and its metabolite, ritalinic acid) in the urine were relatively constant (63–78% of the doses), suggesting that the changes in AUC with dose may not be due to a change in the intestinal absorption of racemic methylphenidate.
We conclude that the nonlinear kinetics of (+)-methylphenidate may be due to saturation of its presystemic elimination.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barkley RA (1977) A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry Allied Discip 18: 137–165
Daly DD, Yoss RE (1956) The treatment of narcolepsy with methylphenylpiperidylacetate: a preliminary report. Staff Meeting of the Mayo Clinic 31: 620–626
Yoss RE, Daly D (1956) Treatment of narcolepsy with Ritalin. Neurology 9: 171–173
Honda Y, Hishikawa Y, Takahashi Y (1979) Long-term treatment of narcolepsy with methylphenidate (Ritalin). Curr Ther Res 25: 288–298
Patrick KS, Kilts CD, Breese GR (1987) Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241: 152–158
Faraj BA, Israili ZH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA, Dayton PG (1974) Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther 191: 535–547
Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, Breese GR (1983) Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 226: 382–386
Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG (1979) Pharmacokinetics of methylphenidate in hyperkinetic children. Br J Clin Pharmacol 8: 571–576
Redalieu E, Bartlett MF, Waldes LM, Darrow WR, Egger H, Wagner WE (1982) A study of methylphenidate in man with respect to its major metabolite. Drug Metab Disp 10: 708–709
Gualtieri CT, Hicks RE, Patrick K, Schroeder SR, Breese GR (1984) Clinical correlates of methylphenidate blood levels. Ther Drug Monit 6: 379–392
Aoyama T, Kotaki H, Honda Y, Nakagawa F (1990) Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J Pharm Sci 79: 465–469
Chan YM, Soldin SJ, Swanson JM, Deber CM, Thiessen JJ, Macleod S (1980) Gas chromatographic/mass spectrometric analysis of methylphenidate (Ritalin) in serum. Clin Biochem 13: 266–272
Srinivas NR, Quinn D, Hubbard JW, Midha KK (1987) Stereoselective disposition of methylphenidate in children with attention-deficit disorder. J Pharmacol Exp Ther 241: 300–306
Hubbard JW, Srinivas NR, Quinn D, Midha KK (1989) Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder. J Pharm Sci 11: 944–947
Aoyama T, Kotaki H, Iga T (1990) Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic methylphenidate to rats. J Pharmacobio-Dyn 13: 647–652
Nakajima K, Kotaki H, Saitoh Y, Nakagawa F (1986) Determination of methylphenidate and its metabolite in plasma by gas chromatography-chemical ionization mass spectrometry. Chem Pharm Bull 34: 1701–1708
Lim HK, Hubbard JW, Midha KK (1986) Development of enantioselective gas chromatographic quantitation assay for dl-threo-methylphenidate in biological fluids. J Chromatogr 378: 109–123
Aoyama T, Kotaki H, Saitoh Y (1989) Gas chromatographic-mass spectrometric analysis of threo-methylphenidate enantiomers in plasma. J Chromatogr 494: 420–423
Aoyama T, Kotaki H, Iga T (1990) Effect of dose on first pass effect of methylphenidate enantiomers in rats. Xenobio-Metab Dispos 5: 527
Kotaki H, Aoyama T, Nakazato F, Saitoh Y, Nakagawa F (1988) Interaction in tissue distribution between methylphenidate and pemoline. II. Effects of methylphenidate or its metabolite on plasma and tissue concentration of pemoline in the rat. Chem Pharm Bull 36: 4560–4566
Wharton RN, Perel JM, Dayton PG, Malitz S (1971) A potential clinical use for methylphenidate with tricyclic antidepressants. Amer J Psychiatry 127: 1619–1625
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aoyama, T., Kotaki, H., Sasaki, T. et al. Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur J Clin Pharmacol 44, 79–84 (1993). https://doi.org/10.1007/BF00315285
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315285